CXCL8 and cancer: In preclinical studies, IL-8 blockade with BMS-986253 has been shown to reduce the recruitment of polymorphonuclear MDSC, revert mesenchymal transition, and enhance susceptibility of cancer cells to immune mediated lysis [92].